Immatics · pitchdeck
Immatics | Investor Presentation Deck | 75 slides
75 pages · 5 arc beats · 3 loops
Immatics | Investor Presentation Deck | 75 slides
Immatics · 2023-11 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
151015202530354045505560657075
Deck intelligence map
5 coverage by narrative range · generated from this deck JSON
Narrative range 35 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 19 hits — 0/3 slides
66.7% 2/3 slides 33.3% 1/3 slides 100% 3/3 slides · 4 hits — 0/3 slides
Solution 10 slides 100% 10/10 slides 100% 10/10 slides · 55 hits — 0/10 slides
40% 4/10 slides 60% 6/10 slides 100% 10/10 slides · 13 hits — 0/10 slides
Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 12 hits — 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides · 4 hits — 0/2 slides
Traction 18 slides 100% 18/18 slides 100% 18/18 slides · 99 hits — 0/18 slides
61.1% 11/18 slides 16.7% 3/18 slides 100% 18/18 slides 33.3% 6/18 slides Team 2 slides 100% 2/2 slides 100% 2/2 slides · 17 hits — 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides — 0/2 slides
Slide inventory
75 every slide · same image gating as the playbook
04
The slide uses a vertical timeline structure to organize clinical catalysts by asset.plan_implementation
Open slide detailBeat · Problem
05
The slide uses a split-screen visual comparison to contrast traditional antibody approaches with the company's TCR-based platform.present_solution
Open slide detailBeat · Problem
06
The slide uses a process-flow diagram to contrast personalized autologous therapy with off-the-shelf bispecific therapy.compare_peers
Open slide detailBeat · Solution
07
The slide uses a Gantt-style visualization to show the progress of various drug candidates across different clinical phases.plan_implementation
Open slide detailBeat · Solution
08
The slide outlines a partnership structure involving three distinct therapeutic approaches and a financial deal structure.present_solution
Open slide detailBeat · Solution
09
The slide uses a timeline framework to demonstrate historical traction and partnership growth.show_traction
Open slide detailBeat · Solution
10
The slide uses a list-based comparison to show market potential for specific drug targets.size_opportunity
Open slide detailBeat · Solution
11
The slide uses a table to show market opportunity (prevalence) and a diagram to illustrate the mechanism of action for two different drug platforms.size_opportunity
Open slide detailBeat · Solution
13
The slide uses a combination of a biological mechanism diagram, a checklist of target criteria, and histological images to validate the therapeutic target.present_solution
Open slide detailBeat · Solution
14
The slide uses a circular process diagram to illustrate the therapy lifecycle, followed by a zoomed-in molecular interaction diagram.present_solution
Open slide detailBeat · Solution
15
Includes clinical trial screening data for specific cancer types.plan_implementation
16
The slide uses a table to compare patient demographics and clinical characteristics across different cancer types, specifically focusing on the sufficiency of tanalyze_data
Open slide detailBeat · Traction
17
Slide compares two generations of therapy; includes clinical metrics like cORR and mDOR.show_traction
Open slide detailBeat · Traction
18
The slide uses a process-flow diagram to distinguish between two generations of TCR-T therapies and their respective trial phases.establish_context
Open slide detailBeat · Traction
19
The table highlights key clinical metrics including ORR, cORR, mDOR, and mFU for various patient subgroups.analyze_data
Open slide detailBeat · Traction
21
Data cut-off Sep 30, 2023. N=16 patients.analyze_data
22
Data cut-off Sep 30, 2023. Includes extensive footnotes regarding methodology and specific patient cases.analyze_data
23
Includes waterfall plot for BOR and spider plot for response over time. Data cut-off Sep 30, 2023.show_traction
24
The slide uses a matrix structure to define the patient population and market opportunity.size_opportunity
26
The slide uses a biological diagram to illustrate the synergy between CD4 and CD8 T cells in inducing tumor cell death.present_solution
Open slide detailBeat · Traction
27
The slide uses two line charts to demonstrate the superior durability of CD4 T cells in a serial killing assay.present_solution
Open slide detailBeat · Traction
28
Includes specific clinical details on Grade 3/4 events for two patients in the highest dose cohort (DL4b).analyze_data
Open slide detailBeat · Traction
30
Includes waterfall plot and spider plot (longitudinal response). Data cut-off Sep 30, 2023.show_traction
Open slide detailBeat · Traction
31
Includes p-values for statistical significance across four distinct clinical metrics.show_traction
Open slide detailBeat · Traction
33
The slide uses a two-row layout to contrast GEN1 and GEN2 therapies, each with a 'Next Step' callout.show_traction
Open slide detailBeat · Traction
34
Uses a ridge plot (joyplot) to visualize distribution of PRAME expression across 7 cancer types.size_opportunity
Open slide detailLoop · Quick Win Big Bet
35
The slide uses a chevron-based process flow to represent a phased development roadmap.plan_implementation
Open slide detailLoop · Quick Win Big Bet
36
The left side uses a funnel diagram to represent the manufacturing process steps.present_solution
Open slide detailLoop · Quick Win Big Bet
37
The table uses a multi-step funnel approach to arrive at the final patient population count.size_opportunity
Open slide detailLoop · Quick Win Big Bet
39
The slide uses a four-column layout to summarize the therapeutic profile of the drug candidate.present_solution
40
Includes histological images of tumor/stroma and a longitudinal bioluminescence imaging study in mice.present_solution
41
The slide features a high-quality photograph of a scientist handling cryogenic materials, reinforcing the 'off-the-shelf' (frozen/stored) nature of the product.transition
42
The slide outlines a manufacturing process for off-the-shelf cell therapy.present_solution
43
The slide uses a bulleted list to define the therapeutic rationale and two line charts to provide empirical evidence.present_solution
Open slide detailLoop · Why Now
45
The slide uses a structural diagram to explain the three components of the molecule and a process diagram to show the biological interaction.present_solution
Open slide detailLoop · Why Now
46
Includes a schematic diagram of the bispecific molecule on the left.present_solution
47
The chart shows a clear performance advantage for the blue line (TCER®) over the grey lines.present_solution
48
The chart uses a broken axis to show early time points and late-stage tumor volume divergence.present_solution
49
The slide uses a 3x4 grid of line charts to demonstrate the safety profile of the proprietary TCER format.present_solution
50
The slide uses a horizontal arrow-based process flow to categorize programs by development stage (Clinical vs Preclinical).plan_implementation
51
Includes ISH images, a prevalence table, and a dot plot comparing peptide density.present_solution
52
Includes study design timeline, histology details, and comparative tumor volume charts (group averages vs individual mice).show_traction
53
The slide illustrates the methodology for PK analysis (injection, sampling, quantification) and presents the resulting concentration-time curve.analyze_data
54
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.plan_implementation
55
The slide uses four dose-response curves to show cytotoxicity against different target copy numbers.present_solution
56
The chart uses a broken x-axis between -29 and 0. The legend indicates four distinct treatment groups.show_traction
57
The slide uses a log-linear plot to demonstrate drug clearance over time.show_traction
58
The slide outlines a standard clinical trial progression from overview to dose escalation and expansion.plan_implementation
60
The slide uses a visual metaphor of cell-to-cell interaction to illustrate the therapeutic mechanism.present_solution
61
The funnel is represented as a series of concentric circles/segments.present_solution
62
The chart is a dot plot showing quantitative target density (CpC) for two different peptide targets.present_solution
63
The slide illustrates the mechanism of action for two therapeutic modalities derived from the same TCR discovery platform.present_solution
64
The slide uses a comparative framework to explain the safety profile of their technology platform.present_solution
65
The slide uses a flywheel-style circular diagram to represent the iterative nature of the data platform.present_solution
66
The slide highlights the breadth of the company's intellectual property protection across major global regions.establish_context
68
The slide uses a grid layout with headshots and professional titles for 9 executives.other
Open slide detailBeat · Team
69
The slide highlights the trans-atlantic nature of the organization with specific operational focus areas per site.establish_context
Open slide detailBeat · Team
71
Includes waterfall plot and spider plot for RECIST 1.1 response metrics.analyze_data
72
Includes waterfall plot and spider plot (change in tumor size over time).show_traction